SlideShare a Scribd company logo
Peritoneal Dialysis Prescription
               &
          Adequatcy
     Piti Niyomsirivanich,MD.
• Peritoneal dialysis prescription
  – Acute
     •   Introduction
     •   Peritoneal Catheter
     •   Use of automate cycler
     •   Prescribing acute peritoneal dialysis
     •   Complications
• Chronic
  • Choice of PD treatment modality
     – Modalities of PD therapy CAPD , APD ,hybrid
     – CAPD or PD ?
  • Choice of prescription
     –   Clearance targets
     –   Measurement of clearance
     –   Determinants of clearance
     –   prescription
  • Nutritional issues in PD
Acute peritoneal dialysis
      presciption
• Peritoneal dialysis prescription
  – Acute
     •   Introduction
     •   Peritoneal Catheter
     •   Use of automate cycler
     •   Prescribing acute peritoneal dialysis
     •   Complications
Introduction
• Acute Peritoneal Dialysis
  – Nonvascular alternative for dialysis
  – Acutely less efficient than conventional
    hemodialysis
Adventage / Disadventage
Adventage                              Disadventage

   •Technically simpler than that of   •Less efficient than hemodialysis
   hemodialysis                        (flash pulmonary edema , drug
   •Doesn’t require highly trained     overdose , acidosis ,hyperkalemia ,
   personnel or expensive, complex     catabolic patient)
   equipment                           •Protein loss  malnourished
   •Can be instituted quickly          •Hyperglycemia
   •Avoids the potential problems
   related to vascular
        hemorrhage , air embolism      •Serious morbidity (30%) and
   , thrombosis , infection            mortality (5%) attributed Acute PD
   •Lower likelyhood of hypotensive    and HD are similar
   episodes
Indications
• Acute renal failure
• Benefit in volume overload with
  cardiovascular compromise
• Hypothermia
• Hemorrhagic pancreatitis
• Most beneficial in Rx of hemodynamically
  unstable
Contraindications
• Recent surgery requiring abdominal drains
• Known fecal or fungal peritonitis
• Pleuroperitoneal fistula

• Relative contraindication
  –   Severe hypercatabolic states
  –   Abdominal wall cellulitis
  –   Adynamic ileus
  –   Presence of abdominal adhesions or fibrosis
  –   New aortic prosthesis
• Peritoneal dialysis prescription
  – Acute
     •   Introduction
     •   Peritoneal Catheter
     •   Use of automate cycler
     •   Prescribing acute peritoneal dialysis
     •   Complications
Peritoneal catheter
• Pts. With
  – multiorgan system failure
                                      Can be anticipated
  – Prolong period of renal failure
• initial insertion of a Tenckhoff catheter
  (preferred > uncuffed temporary catheter) is
  recommended
• Peritoneal dialysis prescription
  – Acute
     •   Introduction
     •   Peritoneal Catheter
     •   Use of automate cycler
     •   Prescribing acute peritoneal dialysis
     •   Complications
Use of automated cyclers
• Traditionally been done using manual exchanged

• Automated cyclers are being used instead
   – Saving nursing time (30-60 minutes exchange time)
• Peritoneal dialysis prescription
  – Acute
     •   Introduction
     •   Peritoneal Catheter
     •   Use of automate cycler
     •   Prescribing acute peritoneal dialysis
     •   Complications
Prescribing acute peritoneal dialysis
• A: Session length
  – In the setting of acute renal failure (catabolic ,
    oliguric ), continuous removal of fluids and solutes
    is required
  – Need for hourly exchange on a continuous basis
    for days or weeks
  – Order for One day
Standard order for 1 day
Exchange volume
• Average-sized adult can usually tolerate 2L
  exchanges
   – Those with abdominal wall or inguinal hernias, the
     exchange volume should be reduced

• Some may prefer start with smaller volumes(1-
  1.5 L) for the first few exchanges

• The larger volume is , the greater the clearance
  and UF rates
Exchange time
  – Inflow 15 – dwell 30 - drain 15
  – 1 hr.
• Inflow time
  – Gravity
  – 10 min.
  – Prolonged
     • Kinking
     • Inflow resistance
• Inflow pain due to acidic , hypertonic solution
Exchange time
• Dwell period
• Standard dwell period
  – Usual dwell time is 30 min
  – 2L per exchage 48 L per day
  – [Urea] in drained dialysate will be 50-60% of plasma
• More stable patients
  – If Not extremely hypercatabolic state
     •  longer dwell time 1.5-5 hrs


  – At 5 hrs [UREA] dialysate = [UREA]plasma
Exchange time
• Outflow time
  – Gravity
  – 20-30 min
  – Depend on
     •   Total volume
     •   Resistance to outflow
     •   Height
     •   1st exchange
     •   Outflow obstruction
     •   Outflow pain
CEPD (Continouous equilibration
           peritoneal dialysis)
•   Alternative approach
•   Modified version of CAPD
•   Standard manual exchange every 3 to 6 hours
•   Adventage
    – Simplicity
    – Lower cost
    – Less labor-intense
• Disadventage
    – Clearance are less
    – Not be adequate in more catabolic patient
Choosing the dialysis solution
• 1.5% dextrose
  – Sufficient to remove 50-150 of fluid per hour (2L
    ,60min exchange time)
  – UF rate 1.2-3.6 L/day
• 4.25% dextrose
  – UF 300-400 ml/hr
  – Acquired for treatment of CHF
Effect of peritonitis
• During peritonitis
  – Enhanced absorption of glucose
  – Rapidly reducing the osmotic gradient

  – Maintaining the efficiency of UF
     • reduced exchange time
     • More hypertonic exchange
Dialysis Solution additives
• KCl
  – Hypokalemia  KCl 3-5 mEq/L can be added
  – Correction of acidosis K shift  hypokalemia
• Heparin
  – Catheter obstruction due to fibrin
  – 1000 U/2 L
• Insulin
  – Glucose absorbed from the dialysis solution
Insulin
• Antibiotics
  – Intraperitoneal administration
Monitoring fluid balance
Monitor Clearance
• In general
  – BUN should maintain below 80 mg/dl

  – D:P ratio for urea
     • [BUN]dialysate : [BUN]plasma ratio
     • Multiplied by total daily dialysate volume urea daily
       clearance
     • Should be at least 10 ml/min
     • 20-30 ml/min in hypercatabolic patient
• Peritoneal dialysis prescription
  – Acute
     •   Introduction
     •   Peritoneal Catheter
     •   Use of automate cycler
     •   Prescribing acute peritoneal dialysis
     •   Complications
Complications
• Abdominal distention
  – Incomplete drainage
• Peritonitis
  – 12% of cases
  – Occur within first 48 hrs
  – Gram +ve organisms (>50%)
  – Prolong used of Multiple antibiotics  fungus
• Hypotention
  – Removal large amout of fluid
Complications
• Hyperglycemia
  – IP insulin
• Hypernatremia
  – UF generated in PD [Na] 70 mEq/L
  – Increased loss of water
• Hypoalbuminemia
  – Protein loss 10-20 gm /day
  – Early oral or parenteral hyperalimentation should
    be instituted
Adequacy of Peritoneal Dialysis and
   Chronic Peritoneal Dialysis
          Prescription
• Chronic
  • Choice of PD treatment modality
     – Modalities of PD therapy CAPD , APD ,hybrid
     – CAPD or PD ?
  • Choice of prescription
     –   Clearance targets
     –   Measurement of clearance
     –   Determinants of clearance
     –   prescription
  • Nutritional issues in PD
• Choice of modality
  –   CAPD
  –   APD
  –   Variant of APD : CCPD , NIPD
  –   hybrid

• Selection based on
  – Clearance
  – UF
  – Nutritional requirement
Diagrammatic
Representation of various
 continuous ambulatory
 peritoneal dialysis and
  automate peritoneal
        dialysis
Modality of peritoneal dialysis therapy
• CAPD
  – Low cost
  – Freedom from dialysis machinery
  – Continuous therapy and a steady physiologic state
  – Nomalization of blood pressure is possible in most
    patients.
  – Multiple procedural sessions
  – Can be done away from home
  – Episodes of peritonitis
Modality of peritoneal dialysis therapy
• APD
  – CCPD
    • Continuous therapy
    • Need for cycler
    • Complications associated c a prolonged day dwell
        – Excessive resorption of dialysate
            » Icodextrin are useful in day dwell
  – NIPD
    • No dialysis fluid during day time
    • Suitable for patient with good residual renal function
• Hybrid forms of PD
  – CAPD with automated nocturnal exchange
        • A night exchange device


  – APD with additional exchange during the day

• IPD
  – Almost extinct
  – Cycler in hospital 2-3 times weekly duration 12-24 hr
• Chronic
  • Choice of PD treatment modality
     – Modalities of PD therapy CAPD , APD ,hybrid
     – CAPD or PD ?
  • Choice of prescription
     –   Clearance targets
     –   Measurement of clearance
     –   Determinants of clearance
     –   prescription
  • Nutritional issues in PD
CAPD or APD
• Based on
  – Lifestyle ,emplyment , place of residence comfort
    with the cycle technology and family and social
    support
• Previously APD better than APD
  – Na Sieving
     • Risk of net fluid resorption with long day dwells
     • Led to concerns about Na removal with APD
  – Systolic hypertension with APD > CAPD (no
    randomized trial but generalizable)
• Risk of peritonitis
  – Decade ago
     • APD showed less peritonitis
     • But APD techinique improved now


• Relative cost
• Chronic
  • Choice of PD treatment modality
     – Modalities of PD therapy CAPD , APD ,hybrid
     – CAPD or PD ?
  • Choice of prescription
     –   Clearance targets
     –   Measurement of clearance
     –   Determinants of clearance
     –   prescription
  • Nutritional issues in PD
Choice of a prescription
• Clearance targets
  – ADEMEX study
     • 1000 CAPD patients
        – 4X2 L CAPD versus a high peritoneal clearance regimen
        – 2 years
        – Mean Kt/V 1.62 and 2.12 / wk


  A concensus target Kt/V for PD  1.7 /wks
• Chronic
  • Choice of PD treatment modality
     – Modalities of PD therapy CAPD , APD ,hybrid
     – CAPD or PD ?
  • Choice of prescription
     –   Clearance targets
     –   Measurement of clearance
     –   Determinants of clearance
     –   prescription
  • Nutritional issues in PD
Frequency of measurement
• Within 1 month of initiation
• And then q 4 months

• Discordance between Kt/V and CrCl
  – APD
     • Cr has higher molecular weight than urea
• Chronic
  • Choice of PD treatment modality
     – Modalities of PD therapy CAPD , APD ,hybrid
     – CAPD or PD ?
  • Choice of prescription
     –   Clearance targets
     –   Measurement of clearance
     –   Determinants of clearance
     –   prescription
  • Nutritional issues in PD
Determinants of clearance
• Residual renal function
  – Account for as much as 50% of total clearance
  – Preserved in patient on CAPD
     •  ACEI ,ARB
     • Avoid nephrotoxic agents i.e. aminoglycoside
• Peritoneal transport status
  – PET
     • Low transporter  high volume ,long duration dwell
          – Low average
          – High average
     • High transporter  short duration dwell
• Body size
  – Large body size  harder to achieve clearance


• Prescription
  – Change
  – Focus on lifestyle factors
• Chronic
  • Choice of PD treatment modality
     – Modalities of PD therapy CAPD , APD ,hybrid
     – CAPD or PD ?
  • Choice of prescription
     –   Clearance targets
     –   Measurement of clearance
     –   Determinants of clearance
     –   prescription
  • Nutritional issues in PD
CAPD
• Initial
   – 4x2 L or 4x2.5 in larger patients
   – Increase peritoneal Kt/V in CAPD
      • Increasing exchange volumes
            – Increase backpain
            – Abdominal distention
            – Shortness of breath
      • Increasing the frequency of daily exchange
            – Most CAPD pts. Do 4 exchange daily
            – 45 lead to burn out (alt. night exchange)
      • Increase the tonicity of dialysis solution
            – Increase UF and clearance
APD
• 10-12 L daily (15 L in larger)
• Good residual renal function  NIPD
• High transporter  short day time/second
  dwell
• Typical cycler time is 8-10 hrs
  – dwell volumes 2 L
Increase clearance of APD
• Introduction of a day dwell
  – NIPD
     • Adding day dwell  increase Kt/V and CrCl by 25%-50%
     • Disadventage
        – In high transporter  increase net fluid resorption
        – Icodextrin or shortening day dwell

• Increase dwell volumes on cycler
  – Because patients are supine during cyclingtolerate
    larger dwell volume
  – 4X2.5 L per session is better than 5X2 L per session
Increase clearance of APD
• Time on cycler
   – The longer time ,the better clearance


• Increasing frequency of cycles
   – More frequent cycle  increase clearance on APD
   – But More frequent cycle Dialysis time lost


• Increasing dialysis solution tonicity
   – concern about glocose-related complications arise
Incremental versus maximal prescription

• Incremental approach
  – Suitable when dialysis is being initiated early
  – 2-3 CAPD exchanges daily or a low-volume

  – Less costly and less onerous
  – Decrease total glucose exposure and risk of peritonitis

  – Require regular monitoring of resiual function
     • To ensure that the clearance achieved doesn’t below target
       levels
Empirical versus Modeled approach

• Modeled approach
•     collecting patient anthropometric data , PET , residual
  renal function

• Computer program uses the data to predict

• Actual clearance still have to be measure
•     because discrepancy between actual and modeled
Empirical versus Modeled approach

• Empirical approach
   – Physician uses knowledge of the patient’s size , residual renal function
     , and peritoneal transport status
   – And choose a resonable prescription

   – Advantage
       • Less trial and error
       • Earlier identification of an appropriate prescription
Prescription pitfalls in peritoneal dialysis
• Loss of residual renal function
    – Not monitored closely enough

• Noncompliance
    – No single test that identifies this problem
    – Serial measurement of 24-hr dialysate plus urinary Cr excretion
• High serum creatinine despite good clearances
    – Kt/V > 1.7/wk but serum Cr > 12-15
    – Non compliance

    – Kt/V high and CrCl low
    – Residual renal function fades away

    – Hight lean body mass
• Inappropriate switch form CAPD to APD
  – Particular in low transporter


• Inadequate attention to fluid removal
  – Particular in high , high-average transporter and
    long dwells that result in net fluid resorption
• Chronic
  • Choice of PD treatment modality
     – Modalities of PD therapy CAPD , APD ,hybrid
     – CAPD or PD ?
  • Choice of prescription
     –   Clearance targets
     –   Measurement of clearance
     –   Determinants of clearance
     –   prescription
  • Nutritional issues in PD
Nutritional Issues in PD
• nPNA
  – Normalized protein equivalent of nitrogen appearance
  – Include
     • Serum albumin
     • Subjective global assessment
     • Lean body mass
  – Measure 24 hr of dialysate and urine (intake
    output)
  – Bergstrom
  – Recommend 1.2 gm/kg/day
• Caloric intake
  – = dietary intake + glucose absorbed
  – 35 kcal/kg/day
  – 10-30% come from glucose (depend on tonicity)
Bergstrom formulas
• 1) PNA (g per day)=20.1 + 7.5 UNA (g per day)
or
• 2) PNA (g per day)= 15.1 + 6.95 UNA + dialysate
   protein losses (g per day)

• UNA = urinary nitrogen losses (g/day) + dialysiate
  urea nitrogen losses

• 1) if dialysate protein losses are unknown
• 2) if dialysate protein losses are known
Serum albumin
• Strongest predictors of patient survival on PD
• Influences
  – dialysate albumin losses
  – Inflammation
  – More than dietary protein intake
Subject global assessment
• Simple clinical tool
• Predict patient outcome
• KDOQI , Canadian Society
Creatinine excretion
• 24 hr urine and dialysate collections
Treatment of malnutrition
• Dietitian support
   – Dietition to ensure adequate protein intake
• Nutritional Supplement

• Promotility agent
   – Gastric emptying is impaired
• Anabolic steroid
   – 1 RCT ,Nandrolone 100 mg IM weekly for 6 months 
     improve lean body mass
• Amino acid
   – amino acid based dwell

More Related Content

What's hot

Adequacy of peritoneal dialysis and chronic peritoneal dialysis
Adequacy of peritoneal dialysis and chronic peritoneal dialysisAdequacy of peritoneal dialysis and chronic peritoneal dialysis
Adequacy of peritoneal dialysis and chronic peritoneal dialysis
IPMS- KMU KPK PAKISTAN
 
Fluid management in pd patient
Fluid management in pd patientFluid management in pd patient
Fluid management in pd patient
FarragBahbah
 
Dialysis prescription
Dialysis prescriptionDialysis prescription
Dialysis prescription
Dr. Prem Mohan Jha
 
Physiological function of pd
Physiological function of pdPhysiological function of pd
Physiological function of pd
Ahmed Salah
 
Basics of peritoneal dialysis
Basics of peritoneal dialysisBasics of peritoneal dialysis
Basics of peritoneal dialysisVishal Golay
 
Renal Replacement Therapy: modes and evidence
Renal Replacement Therapy: modes and evidenceRenal Replacement Therapy: modes and evidence
Renal Replacement Therapy: modes and evidence
Mohd Saif Khan
 
Dialysis dose prescription (the basics) dr ujjawal
Dialysis dose prescription (the basics) dr ujjawalDialysis dose prescription (the basics) dr ujjawal
Dialysis dose prescription (the basics) dr ujjawalUjjawal Roy
 
Pd aki 2019
Pd aki 2019Pd aki 2019
Pd aki 2019
FarragBahbah
 
Basics of Continuous Renal Replacement Therapy
Basics of Continuous Renal Replacement Therapy Basics of Continuous Renal Replacement Therapy
Basics of Continuous Renal Replacement Therapy
Muhammad Asim Rana
 
Hd Prescription
Hd PrescriptionHd Prescription
Hd Prescription
MNDU net
 
How to improve Peritoneal dialysis adequacy
How to improve Peritoneal dialysis adequacyHow to improve Peritoneal dialysis adequacy
How to improve Peritoneal dialysis adequacy
Ahmed Mostafa Taha Borham
 
CRRT
CRRTCRRT
Adequacy of haemodialysis
Adequacy of haemodialysisAdequacy of haemodialysis
Adequacy of haemodialysis
Dr Narinder Sharma
 
Infective Complications In Pd
Infective Complications In PdInfective Complications In Pd
Infective Complications In Pd
edwinchowyw
 
Capd peritonitis mortalty
Capd peritonitis mortaltyCapd peritonitis mortalty
Capd peritonitis mortaltyxinnirah
 
Dr alaa saleh complications of peritoneal dialysis (2)
Dr alaa saleh   complications of peritoneal dialysis (2)Dr alaa saleh   complications of peritoneal dialysis (2)
Dr alaa saleh complications of peritoneal dialysis (2)
FarragBahbah
 
Patient selection and training for peritoneal dialysis
Patient selection  and training for peritoneal dialysisPatient selection  and training for peritoneal dialysis
Patient selection and training for peritoneal dialysis
Ayman Seddik
 
Anticoagulation in hemodialysis
Anticoagulation in hemodialysisAnticoagulation in hemodialysis
Anticoagulation in hemodialysisVishal Ramteke
 
Exit site infection in peritoneal dialysis patient
Exit site infection in peritoneal dialysis patientExit site infection in peritoneal dialysis patient
Exit site infection in peritoneal dialysis patient
IPMS- KMU KPK PAKISTAN
 
Complications of peritoneal dialysis
Complications of peritoneal dialysisComplications of peritoneal dialysis
Complications of peritoneal dialysis
Hofstra Northwell School of Medicine
 

What's hot (20)

Adequacy of peritoneal dialysis and chronic peritoneal dialysis
Adequacy of peritoneal dialysis and chronic peritoneal dialysisAdequacy of peritoneal dialysis and chronic peritoneal dialysis
Adequacy of peritoneal dialysis and chronic peritoneal dialysis
 
Fluid management in pd patient
Fluid management in pd patientFluid management in pd patient
Fluid management in pd patient
 
Dialysis prescription
Dialysis prescriptionDialysis prescription
Dialysis prescription
 
Physiological function of pd
Physiological function of pdPhysiological function of pd
Physiological function of pd
 
Basics of peritoneal dialysis
Basics of peritoneal dialysisBasics of peritoneal dialysis
Basics of peritoneal dialysis
 
Renal Replacement Therapy: modes and evidence
Renal Replacement Therapy: modes and evidenceRenal Replacement Therapy: modes and evidence
Renal Replacement Therapy: modes and evidence
 
Dialysis dose prescription (the basics) dr ujjawal
Dialysis dose prescription (the basics) dr ujjawalDialysis dose prescription (the basics) dr ujjawal
Dialysis dose prescription (the basics) dr ujjawal
 
Pd aki 2019
Pd aki 2019Pd aki 2019
Pd aki 2019
 
Basics of Continuous Renal Replacement Therapy
Basics of Continuous Renal Replacement Therapy Basics of Continuous Renal Replacement Therapy
Basics of Continuous Renal Replacement Therapy
 
Hd Prescription
Hd PrescriptionHd Prescription
Hd Prescription
 
How to improve Peritoneal dialysis adequacy
How to improve Peritoneal dialysis adequacyHow to improve Peritoneal dialysis adequacy
How to improve Peritoneal dialysis adequacy
 
CRRT
CRRTCRRT
CRRT
 
Adequacy of haemodialysis
Adequacy of haemodialysisAdequacy of haemodialysis
Adequacy of haemodialysis
 
Infective Complications In Pd
Infective Complications In PdInfective Complications In Pd
Infective Complications In Pd
 
Capd peritonitis mortalty
Capd peritonitis mortaltyCapd peritonitis mortalty
Capd peritonitis mortalty
 
Dr alaa saleh complications of peritoneal dialysis (2)
Dr alaa saleh   complications of peritoneal dialysis (2)Dr alaa saleh   complications of peritoneal dialysis (2)
Dr alaa saleh complications of peritoneal dialysis (2)
 
Patient selection and training for peritoneal dialysis
Patient selection  and training for peritoneal dialysisPatient selection  and training for peritoneal dialysis
Patient selection and training for peritoneal dialysis
 
Anticoagulation in hemodialysis
Anticoagulation in hemodialysisAnticoagulation in hemodialysis
Anticoagulation in hemodialysis
 
Exit site infection in peritoneal dialysis patient
Exit site infection in peritoneal dialysis patientExit site infection in peritoneal dialysis patient
Exit site infection in peritoneal dialysis patient
 
Complications of peritoneal dialysis
Complications of peritoneal dialysisComplications of peritoneal dialysis
Complications of peritoneal dialysis
 

Similar to PD prescription

Penilaian Adekuasi, Kegagalan Membran, Penanganan Peritonitis pada CAPD, Sert...
Penilaian Adekuasi, Kegagalan Membran, Penanganan Peritonitis pada CAPD, Sert...Penilaian Adekuasi, Kegagalan Membran, Penanganan Peritonitis pada CAPD, Sert...
Penilaian Adekuasi, Kegagalan Membran, Penanganan Peritonitis pada CAPD, Sert...
YuyunRasulong1
 
Laboratory role in renal replacement therapy.pptx
Laboratory role in renal replacement therapy.pptxLaboratory role in renal replacement therapy.pptx
Laboratory role in renal replacement therapy.pptx
JyotiSharma560718
 
Pediatric renal replacement therapy in the icu
Pediatric renal replacement therapy in the icuPediatric renal replacement therapy in the icu
Pediatric renal replacement therapy in the icuBharathi Balachander
 
Peritoneal dialysis by Dr. Basil Tumaini
Peritoneal dialysis by Dr. Basil TumainiPeritoneal dialysis by Dr. Basil Tumaini
Peritoneal dialysis by Dr. Basil Tumaini
Basil Tumaini
 
CAPD 3 Abdul Rahman .pptx
CAPD 3 Abdul Rahman .pptxCAPD 3 Abdul Rahman .pptx
CAPD 3 Abdul Rahman .pptx
YuyunRasulong1
 
Ckd dialysis diet in ckd patient education
Ckd dialysis diet in ckd patient educationCkd dialysis diet in ckd patient education
Ckd dialysis diet in ckd patient education
Nilesh Jadhav
 
Renal replacement in children
Renal replacement in childrenRenal replacement in children
Renal replacement in children
Lokeshnrgowda Lokesh
 
5_6125448697896502769.pptx
5_6125448697896502769.pptx5_6125448697896502769.pptx
5_6125448697896502769.pptx
DeepshikhaKar1
 
Management of Chronic Kidney disease Dialysis & Transplantation
Management of Chronic Kidney disease Dialysis & Transplantation Management of Chronic Kidney disease Dialysis & Transplantation
Management of Chronic Kidney disease Dialysis & Transplantation
YMC Medicine
 
Renal Replacement therapy in the ICU
Renal Replacement therapy in the ICURenal Replacement therapy in the ICU
Renal Replacement therapy in the ICU
Syed Hussain
 
Kidney Failure Treatment, Patient Education, and Course Summary
Kidney Failure Treatment, Patient Education, and Course SummaryKidney Failure Treatment, Patient Education, and Course Summary
Kidney Failure Treatment, Patient Education, and Course Summary
mustashoka
 
PD THE ROAD LESS TRAVELLED Dr Ayman Seddik 2.pdf
PD THE ROAD LESS TRAVELLED Dr Ayman Seddik 2.pdfPD THE ROAD LESS TRAVELLED Dr Ayman Seddik 2.pdf
PD THE ROAD LESS TRAVELLED Dr Ayman Seddik 2.pdf
Ayman Seddik
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
HAMAD DHUHAYR
 
Acute kidney injury and renal replacement therapies [autosaved]
Acute kidney injury and renal replacement therapies [autosaved]Acute kidney injury and renal replacement therapies [autosaved]
Acute kidney injury and renal replacement therapies [autosaved]
hood ibanda
 
Rrt dr.sarmistha
Rrt dr.sarmisthaRrt dr.sarmistha
Rrt dr.sarmistha
sarmistha panigrahi
 
peritoneal dialysis, management of chronic renal failure
peritoneal dialysis, management of chronic renal failureperitoneal dialysis, management of chronic renal failure
peritoneal dialysis, management of chronic renal failure
Sapana Shrestha
 
Renal replacement therapy in the ICU
Renal replacement therapy in the ICURenal replacement therapy in the ICU
Renal replacement therapy in the ICUmeducationdotnet
 
Peritoneal dialysis in children
Peritoneal dialysis in childrenPeritoneal dialysis in children
Peritoneal dialysis in children
Nakisa Hooman
 
Adpkd2
Adpkd2Adpkd2
Adpkd2
Ajay Kurian
 
PCP in a Box - Module 3.pptx
PCP in a Box - Module 3.pptxPCP in a Box - Module 3.pptx
PCP in a Box - Module 3.pptx
Binti22
 

Similar to PD prescription (20)

Penilaian Adekuasi, Kegagalan Membran, Penanganan Peritonitis pada CAPD, Sert...
Penilaian Adekuasi, Kegagalan Membran, Penanganan Peritonitis pada CAPD, Sert...Penilaian Adekuasi, Kegagalan Membran, Penanganan Peritonitis pada CAPD, Sert...
Penilaian Adekuasi, Kegagalan Membran, Penanganan Peritonitis pada CAPD, Sert...
 
Laboratory role in renal replacement therapy.pptx
Laboratory role in renal replacement therapy.pptxLaboratory role in renal replacement therapy.pptx
Laboratory role in renal replacement therapy.pptx
 
Pediatric renal replacement therapy in the icu
Pediatric renal replacement therapy in the icuPediatric renal replacement therapy in the icu
Pediatric renal replacement therapy in the icu
 
Peritoneal dialysis by Dr. Basil Tumaini
Peritoneal dialysis by Dr. Basil TumainiPeritoneal dialysis by Dr. Basil Tumaini
Peritoneal dialysis by Dr. Basil Tumaini
 
CAPD 3 Abdul Rahman .pptx
CAPD 3 Abdul Rahman .pptxCAPD 3 Abdul Rahman .pptx
CAPD 3 Abdul Rahman .pptx
 
Ckd dialysis diet in ckd patient education
Ckd dialysis diet in ckd patient educationCkd dialysis diet in ckd patient education
Ckd dialysis diet in ckd patient education
 
Renal replacement in children
Renal replacement in childrenRenal replacement in children
Renal replacement in children
 
5_6125448697896502769.pptx
5_6125448697896502769.pptx5_6125448697896502769.pptx
5_6125448697896502769.pptx
 
Management of Chronic Kidney disease Dialysis & Transplantation
Management of Chronic Kidney disease Dialysis & Transplantation Management of Chronic Kidney disease Dialysis & Transplantation
Management of Chronic Kidney disease Dialysis & Transplantation
 
Renal Replacement therapy in the ICU
Renal Replacement therapy in the ICURenal Replacement therapy in the ICU
Renal Replacement therapy in the ICU
 
Kidney Failure Treatment, Patient Education, and Course Summary
Kidney Failure Treatment, Patient Education, and Course SummaryKidney Failure Treatment, Patient Education, and Course Summary
Kidney Failure Treatment, Patient Education, and Course Summary
 
PD THE ROAD LESS TRAVELLED Dr Ayman Seddik 2.pdf
PD THE ROAD LESS TRAVELLED Dr Ayman Seddik 2.pdfPD THE ROAD LESS TRAVELLED Dr Ayman Seddik 2.pdf
PD THE ROAD LESS TRAVELLED Dr Ayman Seddik 2.pdf
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 
Acute kidney injury and renal replacement therapies [autosaved]
Acute kidney injury and renal replacement therapies [autosaved]Acute kidney injury and renal replacement therapies [autosaved]
Acute kidney injury and renal replacement therapies [autosaved]
 
Rrt dr.sarmistha
Rrt dr.sarmisthaRrt dr.sarmistha
Rrt dr.sarmistha
 
peritoneal dialysis, management of chronic renal failure
peritoneal dialysis, management of chronic renal failureperitoneal dialysis, management of chronic renal failure
peritoneal dialysis, management of chronic renal failure
 
Renal replacement therapy in the ICU
Renal replacement therapy in the ICURenal replacement therapy in the ICU
Renal replacement therapy in the ICU
 
Peritoneal dialysis in children
Peritoneal dialysis in childrenPeritoneal dialysis in children
Peritoneal dialysis in children
 
Adpkd2
Adpkd2Adpkd2
Adpkd2
 
PCP in a Box - Module 3.pptx
PCP in a Box - Module 3.pptxPCP in a Box - Module 3.pptx
PCP in a Box - Module 3.pptx
 

More from ปิติ นิยมศิริวนิช

Radial artery patency after transradial catheterization
Radial artery patency after transradial catheterizationRadial artery patency after transradial catheterization
Radial artery patency after transradial catheterization
ปิติ นิยมศิริวนิช
 
Overview of peritoneal dialysis
Overview of peritoneal dialysisOverview of peritoneal dialysis
Overview of peritoneal dialysis
ปิติ นิยมศิริวนิช
 
Dental management in patients receiving anticoagulation or antiplatelet tre...
Dental management  in patients receiving anticoagulation or antiplatelet  tre...Dental management  in patients receiving anticoagulation or antiplatelet  tre...
Dental management in patients receiving anticoagulation or antiplatelet tre...
ปิติ นิยมศิริวนิช
 
Septic shock
Septic shockSeptic shock
Metabolic complications in patients ongoing pd
Metabolic complications in patients ongoing pdMetabolic complications in patients ongoing pd
Metabolic complications in patients ongoing pd
ปิติ นิยมศิริวนิช
 
Financial Skills ทักษะทางการเงินเบื้องต้น
Financial  Skills ทักษะทางการเงินเบื้องต้นFinancial  Skills ทักษะทางการเงินเบื้องต้น
Financial Skills ทักษะทางการเงินเบื้องต้น
ปิติ นิยมศิริวนิช
 
Disorder Of The Eyes
Disorder Of The EyesDisorder Of The Eyes
Lenient Versus Strict Rate Control ?
Lenient Versus  Strict  Rate  Control ?Lenient Versus  Strict  Rate  Control ?
Lenient Versus Strict Rate Control ?
ปิติ นิยมศิริวนิช
 

More from ปิติ นิยมศิริวนิช (10)

Radial artery patency after transradial catheterization
Radial artery patency after transradial catheterizationRadial artery patency after transradial catheterization
Radial artery patency after transradial catheterization
 
Overview of peritoneal dialysis
Overview of peritoneal dialysisOverview of peritoneal dialysis
Overview of peritoneal dialysis
 
Dental management in patients receiving anticoagulation or antiplatelet tre...
Dental management  in patients receiving anticoagulation or antiplatelet  tre...Dental management  in patients receiving anticoagulation or antiplatelet  tre...
Dental management in patients receiving anticoagulation or antiplatelet tre...
 
Septic shock
Septic shockSeptic shock
Septic shock
 
Metabolic complications in patients ongoing pd
Metabolic complications in patients ongoing pdMetabolic complications in patients ongoing pd
Metabolic complications in patients ongoing pd
 
Financial Skills ทักษะทางการเงินเบื้องต้น
Financial  Skills ทักษะทางการเงินเบื้องต้นFinancial  Skills ทักษะทางการเงินเบื้องต้น
Financial Skills ทักษะทางการเงินเบื้องต้น
 
Disorder Of The Eyes
Disorder Of The EyesDisorder Of The Eyes
Disorder Of The Eyes
 
Pericardial Disease
Pericardial DiseasePericardial Disease
Pericardial Disease
 
High Versus Low Dosing Of Oral Colchicine
High  Versus  Low  Dosing Of  Oral  ColchicineHigh  Versus  Low  Dosing Of  Oral  Colchicine
High Versus Low Dosing Of Oral Colchicine
 
Lenient Versus Strict Rate Control ?
Lenient Versus  Strict  Rate  Control ?Lenient Versus  Strict  Rate  Control ?
Lenient Versus Strict Rate Control ?
 

Recently uploaded

BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 

Recently uploaded (20)

BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 

PD prescription

  • 1. Peritoneal Dialysis Prescription & Adequatcy Piti Niyomsirivanich,MD.
  • 2. • Peritoneal dialysis prescription – Acute • Introduction • Peritoneal Catheter • Use of automate cycler • Prescribing acute peritoneal dialysis • Complications
  • 3. • Chronic • Choice of PD treatment modality – Modalities of PD therapy CAPD , APD ,hybrid – CAPD or PD ? • Choice of prescription – Clearance targets – Measurement of clearance – Determinants of clearance – prescription • Nutritional issues in PD
  • 5. • Peritoneal dialysis prescription – Acute • Introduction • Peritoneal Catheter • Use of automate cycler • Prescribing acute peritoneal dialysis • Complications
  • 6. Introduction • Acute Peritoneal Dialysis – Nonvascular alternative for dialysis – Acutely less efficient than conventional hemodialysis
  • 7. Adventage / Disadventage Adventage Disadventage •Technically simpler than that of •Less efficient than hemodialysis hemodialysis (flash pulmonary edema , drug •Doesn’t require highly trained overdose , acidosis ,hyperkalemia , personnel or expensive, complex catabolic patient) equipment •Protein loss  malnourished •Can be instituted quickly •Hyperglycemia •Avoids the potential problems related to vascular hemorrhage , air embolism •Serious morbidity (30%) and , thrombosis , infection mortality (5%) attributed Acute PD •Lower likelyhood of hypotensive and HD are similar episodes
  • 8. Indications • Acute renal failure • Benefit in volume overload with cardiovascular compromise • Hypothermia • Hemorrhagic pancreatitis • Most beneficial in Rx of hemodynamically unstable
  • 9. Contraindications • Recent surgery requiring abdominal drains • Known fecal or fungal peritonitis • Pleuroperitoneal fistula • Relative contraindication – Severe hypercatabolic states – Abdominal wall cellulitis – Adynamic ileus – Presence of abdominal adhesions or fibrosis – New aortic prosthesis
  • 10. • Peritoneal dialysis prescription – Acute • Introduction • Peritoneal Catheter • Use of automate cycler • Prescribing acute peritoneal dialysis • Complications
  • 11. Peritoneal catheter • Pts. With – multiorgan system failure Can be anticipated – Prolong period of renal failure • initial insertion of a Tenckhoff catheter (preferred > uncuffed temporary catheter) is recommended
  • 12. • Peritoneal dialysis prescription – Acute • Introduction • Peritoneal Catheter • Use of automate cycler • Prescribing acute peritoneal dialysis • Complications
  • 13. Use of automated cyclers • Traditionally been done using manual exchanged • Automated cyclers are being used instead – Saving nursing time (30-60 minutes exchange time)
  • 14. • Peritoneal dialysis prescription – Acute • Introduction • Peritoneal Catheter • Use of automate cycler • Prescribing acute peritoneal dialysis • Complications
  • 15. Prescribing acute peritoneal dialysis • A: Session length – In the setting of acute renal failure (catabolic , oliguric ), continuous removal of fluids and solutes is required – Need for hourly exchange on a continuous basis for days or weeks – Order for One day
  • 17. Exchange volume • Average-sized adult can usually tolerate 2L exchanges – Those with abdominal wall or inguinal hernias, the exchange volume should be reduced • Some may prefer start with smaller volumes(1- 1.5 L) for the first few exchanges • The larger volume is , the greater the clearance and UF rates
  • 18. Exchange time – Inflow 15 – dwell 30 - drain 15 – 1 hr. • Inflow time – Gravity – 10 min. – Prolonged • Kinking • Inflow resistance • Inflow pain due to acidic , hypertonic solution
  • 19. Exchange time • Dwell period • Standard dwell period – Usual dwell time is 30 min – 2L per exchage 48 L per day – [Urea] in drained dialysate will be 50-60% of plasma • More stable patients – If Not extremely hypercatabolic state •  longer dwell time 1.5-5 hrs – At 5 hrs [UREA] dialysate = [UREA]plasma
  • 20. Exchange time • Outflow time – Gravity – 20-30 min – Depend on • Total volume • Resistance to outflow • Height • 1st exchange • Outflow obstruction • Outflow pain
  • 21. CEPD (Continouous equilibration peritoneal dialysis) • Alternative approach • Modified version of CAPD • Standard manual exchange every 3 to 6 hours • Adventage – Simplicity – Lower cost – Less labor-intense • Disadventage – Clearance are less – Not be adequate in more catabolic patient
  • 22. Choosing the dialysis solution • 1.5% dextrose – Sufficient to remove 50-150 of fluid per hour (2L ,60min exchange time) – UF rate 1.2-3.6 L/day • 4.25% dextrose – UF 300-400 ml/hr – Acquired for treatment of CHF
  • 23. Effect of peritonitis • During peritonitis – Enhanced absorption of glucose – Rapidly reducing the osmotic gradient – Maintaining the efficiency of UF • reduced exchange time • More hypertonic exchange
  • 24. Dialysis Solution additives • KCl – Hypokalemia  KCl 3-5 mEq/L can be added – Correction of acidosis K shift  hypokalemia • Heparin – Catheter obstruction due to fibrin – 1000 U/2 L • Insulin – Glucose absorbed from the dialysis solution
  • 26. • Antibiotics – Intraperitoneal administration
  • 28. Monitor Clearance • In general – BUN should maintain below 80 mg/dl – D:P ratio for urea • [BUN]dialysate : [BUN]plasma ratio • Multiplied by total daily dialysate volume urea daily clearance • Should be at least 10 ml/min • 20-30 ml/min in hypercatabolic patient
  • 29. • Peritoneal dialysis prescription – Acute • Introduction • Peritoneal Catheter • Use of automate cycler • Prescribing acute peritoneal dialysis • Complications
  • 30. Complications • Abdominal distention – Incomplete drainage • Peritonitis – 12% of cases – Occur within first 48 hrs – Gram +ve organisms (>50%) – Prolong used of Multiple antibiotics  fungus • Hypotention – Removal large amout of fluid
  • 31. Complications • Hyperglycemia – IP insulin • Hypernatremia – UF generated in PD [Na] 70 mEq/L – Increased loss of water • Hypoalbuminemia – Protein loss 10-20 gm /day – Early oral or parenteral hyperalimentation should be instituted
  • 32. Adequacy of Peritoneal Dialysis and Chronic Peritoneal Dialysis Prescription
  • 33. • Chronic • Choice of PD treatment modality – Modalities of PD therapy CAPD , APD ,hybrid – CAPD or PD ? • Choice of prescription – Clearance targets – Measurement of clearance – Determinants of clearance – prescription • Nutritional issues in PD
  • 34. • Choice of modality – CAPD – APD – Variant of APD : CCPD , NIPD – hybrid • Selection based on – Clearance – UF – Nutritional requirement
  • 35. Diagrammatic Representation of various continuous ambulatory peritoneal dialysis and automate peritoneal dialysis
  • 36.
  • 37. Modality of peritoneal dialysis therapy • CAPD – Low cost – Freedom from dialysis machinery – Continuous therapy and a steady physiologic state – Nomalization of blood pressure is possible in most patients. – Multiple procedural sessions – Can be done away from home – Episodes of peritonitis
  • 38. Modality of peritoneal dialysis therapy • APD – CCPD • Continuous therapy • Need for cycler • Complications associated c a prolonged day dwell – Excessive resorption of dialysate » Icodextrin are useful in day dwell – NIPD • No dialysis fluid during day time • Suitable for patient with good residual renal function
  • 39. • Hybrid forms of PD – CAPD with automated nocturnal exchange • A night exchange device – APD with additional exchange during the day • IPD – Almost extinct – Cycler in hospital 2-3 times weekly duration 12-24 hr
  • 40. • Chronic • Choice of PD treatment modality – Modalities of PD therapy CAPD , APD ,hybrid – CAPD or PD ? • Choice of prescription – Clearance targets – Measurement of clearance – Determinants of clearance – prescription • Nutritional issues in PD
  • 41. CAPD or APD • Based on – Lifestyle ,emplyment , place of residence comfort with the cycle technology and family and social support • Previously APD better than APD – Na Sieving • Risk of net fluid resorption with long day dwells • Led to concerns about Na removal with APD – Systolic hypertension with APD > CAPD (no randomized trial but generalizable)
  • 42. • Risk of peritonitis – Decade ago • APD showed less peritonitis • But APD techinique improved now • Relative cost
  • 43. • Chronic • Choice of PD treatment modality – Modalities of PD therapy CAPD , APD ,hybrid – CAPD or PD ? • Choice of prescription – Clearance targets – Measurement of clearance – Determinants of clearance – prescription • Nutritional issues in PD
  • 44. Choice of a prescription • Clearance targets – ADEMEX study • 1000 CAPD patients – 4X2 L CAPD versus a high peritoneal clearance regimen – 2 years – Mean Kt/V 1.62 and 2.12 / wk A concensus target Kt/V for PD  1.7 /wks
  • 45.
  • 46. • Chronic • Choice of PD treatment modality – Modalities of PD therapy CAPD , APD ,hybrid – CAPD or PD ? • Choice of prescription – Clearance targets – Measurement of clearance – Determinants of clearance – prescription • Nutritional issues in PD
  • 47. Frequency of measurement • Within 1 month of initiation • And then q 4 months • Discordance between Kt/V and CrCl – APD • Cr has higher molecular weight than urea
  • 48. • Chronic • Choice of PD treatment modality – Modalities of PD therapy CAPD , APD ,hybrid – CAPD or PD ? • Choice of prescription – Clearance targets – Measurement of clearance – Determinants of clearance – prescription • Nutritional issues in PD
  • 49. Determinants of clearance • Residual renal function – Account for as much as 50% of total clearance – Preserved in patient on CAPD •  ACEI ,ARB • Avoid nephrotoxic agents i.e. aminoglycoside • Peritoneal transport status – PET • Low transporter  high volume ,long duration dwell – Low average – High average • High transporter  short duration dwell
  • 50. • Body size – Large body size  harder to achieve clearance • Prescription – Change – Focus on lifestyle factors
  • 51. • Chronic • Choice of PD treatment modality – Modalities of PD therapy CAPD , APD ,hybrid – CAPD or PD ? • Choice of prescription – Clearance targets – Measurement of clearance – Determinants of clearance – prescription • Nutritional issues in PD
  • 52. CAPD • Initial – 4x2 L or 4x2.5 in larger patients – Increase peritoneal Kt/V in CAPD • Increasing exchange volumes – Increase backpain – Abdominal distention – Shortness of breath • Increasing the frequency of daily exchange – Most CAPD pts. Do 4 exchange daily – 45 lead to burn out (alt. night exchange) • Increase the tonicity of dialysis solution – Increase UF and clearance
  • 53. APD • 10-12 L daily (15 L in larger) • Good residual renal function  NIPD • High transporter  short day time/second dwell • Typical cycler time is 8-10 hrs – dwell volumes 2 L
  • 54. Increase clearance of APD • Introduction of a day dwell – NIPD • Adding day dwell  increase Kt/V and CrCl by 25%-50% • Disadventage – In high transporter  increase net fluid resorption – Icodextrin or shortening day dwell • Increase dwell volumes on cycler – Because patients are supine during cyclingtolerate larger dwell volume – 4X2.5 L per session is better than 5X2 L per session
  • 55. Increase clearance of APD • Time on cycler – The longer time ,the better clearance • Increasing frequency of cycles – More frequent cycle  increase clearance on APD – But More frequent cycle Dialysis time lost • Increasing dialysis solution tonicity – concern about glocose-related complications arise
  • 56. Incremental versus maximal prescription • Incremental approach – Suitable when dialysis is being initiated early – 2-3 CAPD exchanges daily or a low-volume – Less costly and less onerous – Decrease total glucose exposure and risk of peritonitis – Require regular monitoring of resiual function • To ensure that the clearance achieved doesn’t below target levels
  • 57. Empirical versus Modeled approach • Modeled approach • collecting patient anthropometric data , PET , residual renal function • Computer program uses the data to predict • Actual clearance still have to be measure • because discrepancy between actual and modeled
  • 58. Empirical versus Modeled approach • Empirical approach – Physician uses knowledge of the patient’s size , residual renal function , and peritoneal transport status – And choose a resonable prescription – Advantage • Less trial and error • Earlier identification of an appropriate prescription
  • 59. Prescription pitfalls in peritoneal dialysis • Loss of residual renal function – Not monitored closely enough • Noncompliance – No single test that identifies this problem – Serial measurement of 24-hr dialysate plus urinary Cr excretion • High serum creatinine despite good clearances – Kt/V > 1.7/wk but serum Cr > 12-15 – Non compliance – Kt/V high and CrCl low – Residual renal function fades away – Hight lean body mass
  • 60. • Inappropriate switch form CAPD to APD – Particular in low transporter • Inadequate attention to fluid removal – Particular in high , high-average transporter and long dwells that result in net fluid resorption
  • 61. • Chronic • Choice of PD treatment modality – Modalities of PD therapy CAPD , APD ,hybrid – CAPD or PD ? • Choice of prescription – Clearance targets – Measurement of clearance – Determinants of clearance – prescription • Nutritional issues in PD
  • 62. Nutritional Issues in PD • nPNA – Normalized protein equivalent of nitrogen appearance – Include • Serum albumin • Subjective global assessment • Lean body mass – Measure 24 hr of dialysate and urine (intake output) – Bergstrom – Recommend 1.2 gm/kg/day
  • 63. • Caloric intake – = dietary intake + glucose absorbed – 35 kcal/kg/day – 10-30% come from glucose (depend on tonicity)
  • 64. Bergstrom formulas • 1) PNA (g per day)=20.1 + 7.5 UNA (g per day) or • 2) PNA (g per day)= 15.1 + 6.95 UNA + dialysate protein losses (g per day) • UNA = urinary nitrogen losses (g/day) + dialysiate urea nitrogen losses • 1) if dialysate protein losses are unknown • 2) if dialysate protein losses are known
  • 65. Serum albumin • Strongest predictors of patient survival on PD • Influences – dialysate albumin losses – Inflammation – More than dietary protein intake
  • 66. Subject global assessment • Simple clinical tool • Predict patient outcome • KDOQI , Canadian Society
  • 67. Creatinine excretion • 24 hr urine and dialysate collections
  • 68. Treatment of malnutrition • Dietitian support – Dietition to ensure adequate protein intake • Nutritional Supplement • Promotility agent – Gastric emptying is impaired • Anabolic steroid – 1 RCT ,Nandrolone 100 mg IM weekly for 6 months  improve lean body mass • Amino acid – amino acid based dwell